NAD+ Transdermal Patch: Does It Actually Work?

Written by the Nuvirox Research Team

Short answer: NAD+ patches are sold on the idea of slow, steady absorption through the skin, but no published human study has measured blood NAD+ levels after applying one. That's a specific, checkable gap, and it's worth understanding before paying a premium for a delivery method with no pharmacokinetic data behind it, especially compared to oral NAD+ precursors that do.

How is a NAD+ patch supposed to work?

Transdermal patches work by placing a drug or compound in an adhesive layer against the skin, allowing gradual diffusion through the stratum corneum (the skin’s outer barrier) into underlying blood vessels over several hours. This is a real and well-established delivery method — nicotine patches, certain hormone patches, and fentanyl patches used in medical settings all work this way, with published pharmacokinetic data confirming how much drug actually reaches the bloodstream.

The catch is that transdermal delivery works well only for molecules with the right physical properties: generally small (often cited around 500 daltons or less), reasonably lipophilic (fat-soluble), and uncharged. NAD+ itself is a larger, charged dinucleotide molecule (roughly 663 daltons) — properties that make efficient passive diffusion across intact skin genuinely questionable on basic pharmacological grounds, independent of any marketing claim.

What do consumer reviews of NAD+ patches actually say about the evidence?

Even sources written to evaluate these products for consumers are consistent on this point: there is no published pharmacokinetic data measuring blood NAD+ levels after patch application, no controlled trial comparing patches to placebo, and no established dose. Some patches use iontophoresis (a mild electrical current to help drive molecules through skin) rather than passive diffusion, which is a different and more plausible mechanism — but even iontophoretic NAD+ delivery hasn’t been tested in a published human trial.

What human studies actually show

What has been measured: oral NR pharmacokinetics. The clearest human dose-response data in this space comes from oral nicotinamide riboside trials, not any transdermal product. An 8-week randomized trial found 100–1000 mg oral NR dose-dependently raised whole-blood NAD+ by 22–142% with a clean safety profile (Conze D, Brenner C, Kruger CL. Safety and metabolism of long-term administration of NIAGEN (nicotinamide riboside chloride) in a randomized, double-blind, placebo-controlled clinical trial of healthy overweight adults. Sci Rep. 2019;9:9772. doi:10.1038/s41598-019-46120-z), and a separate 6-week crossover trial confirmed the same in older adults (Martens CR, Denman BA, Mazzo MR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018;9(1):1286. doi:10.1038/s41467-018-03421-7).

What has not been measured: transdermal NAD+ or NR pharmacokinetics. A consumer evidence review specifically looking at NAD+ patches concluded that no randomized controlled trials have evaluated NAD+ patches against placebo in humans, that bioavailability through intact skin hasn’t been established, and that no study has measured blood NAD+ levels following patch application (Bolt Pharmacy. Do NAD Patches Work? Evidence and Safety Review. Consumer-facing evidence summary noting absence of published transdermal NAD+ pharmacokinetic or efficacy trials in humans (2026).). That same source notes that safety data specific to transdermal NAD+ delivery is lacking, with most safety assumptions borrowed from oral precursor studies that may not reflect a patch’s actual profile, including unstudied risks like local skin irritation or contact dermatitis at the application site.

What about products claiming 'clinically proven' patch absorption? Any product-specific claim of clinical proof should be traceable to a specific trial with a registered protocol, a control group, and measured blood levels. If a seller can't point to that trial, the claim is marketing language borrowed from unrelated oral-route studies, not evidence about the patch itself. That distinction is worth asking about directly before paying a premium price for a patch format.

An honest comparison to a delivery route that has been studied for other drugs. Transdermal delivery does work well for some compounds — nicotine and certain hormones have well-characterized transdermal pharmacokinetics, including randomized crossover studies measuring exact absorption rates. That existing body of transdermal science shows the delivery method itself is sound in principle; it just hasn’t been applied and measured for NAD+ or its precursors specifically.

What NAD+ Restore won't do

NAD+ Restore is an oral capsule and makes no transdermal delivery claim. This article isn’t asserting that transdermal delivery categorically can’t work for NAD+-related compounds — only that it hasn’t been tested, which is a meaningfully different and more honest statement than either 'it works' or 'it can’t work.'

See a doctor before using any patch product, transdermal or otherwise, if you have sensitive skin, a history of contact dermatitis, or are applying anything near a wound or irritated skin.

Dosing and realistic timelines

No evidence-based transdermal dose exists because no pharmacokinetic study has established one. For oral NR, published human trials support 300–1000 mg daily as both safe and effective for raising blood NAD+ (Conze D, Brenner C, Kruger CL. Safety and metabolism of long-term administration of NIAGEN (nicotinamide riboside chloride) in a randomized, double-blind, placebo-controlled clinical trial of healthy overweight adults. Sci Rep. 2019;9:9772. doi:10.1038/s41598-019-46120-z); NAD+ Restore provides 500 mg NR per serving, within that studied range.

Frequently asked questions

Are NAD+ patches dangerous?

No serious safety signal has been reported, but that’s partly because dedicated safety studies for transdermal NAD+ haven’t been done; local skin irritation is the most commonly reported issue in consumer feedback.

Does iontophoresis change the answer?

Iontophoresis (using a small electrical current to push molecules through skin) is a more plausible delivery mechanism than passive diffusion for a molecule NAD+’s size, but even iontophoretic NAD+ delivery hasn’t been tested in a published clinical trial.

Why do patches claim 12–14 hour absorption windows?

This describes the physical release profile of the adhesive patch material, not a measured blood NAD+ curve; sustained release from the patch doesn’t confirm sustained absorption into circulation.

Is oral NR proven to work better?

It’s not a head-to-head comparison since no trial has tested both routes against each other, but oral NR is the delivery method with actual published human blood-level data behind it.

From Nuvirox

Why we formulated NAD+ Restore

Each 2-capsule serving delivers 500 mg nicotinamide riboside chloride (NR) — one of the two most-researched NAD+ precursors, within the dose range used in published human trials — alongside 150 mg trans-resveratrol and 50 mg quercetin, polyphenols studied alongside NAD+ pathways for cellular health support, plus 10 mg fenugreek-derived galactomannans to support absorption.

Backed by a 60-day money-back guarantee — long enough to actually evaluate it the way the research says you should.

Learn more about NAD+ Restore →

The bottom line

Basic transdermal drug delivery principles raise real, checkable questions about whether NAD+ or its precursors cross intact skin efficiently, and no human trial has answered those questions either way — the same evidence gap we found when we looked at NAD+ nasal spray. Until pharmacokinetic data exists for either delivery format, an oral NAD+ precursor with published dose-response data remains the better-documented option.

References

1. Bolt Pharmacy. Do NAD Patches Work? Evidence and Safety Review. Consumer-facing evidence summary noting absence of published transdermal NAD+ pharmacokinetic or efficacy trials in humans (2026).
2. Conze D, Brenner C, Kruger CL. Safety and metabolism of long-term administration of NIAGEN (nicotinamide riboside chloride) in a randomized, double-blind, placebo-controlled clinical trial of healthy overweight adults. Sci Rep. 2019;9:9772. doi:10.1038/s41598-019-46120-z
3. Martens CR, Denman BA, Mazzo MR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018;9(1):1286. doi:10.1038/s41467-018-03421-7

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical advice.